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Somatic cell nuclear transfer and transcription factor-based reprogramming revert adult cells to an 
embryonic state, and yield pluripotent stem cells that can generate all tissues. These two 
reprogramming methods reset genomic methylation, an epigenetic modification of DNA that 
influences gene expression, by different mechanisms and kinetics, leading us to hypothesize that 
the resulting pluripotent stem cells might have different properties. Here we observe that low 
passage induced pluripotent stem cells (iPSC) derived by factor-based reprogramming harbor 
residual DNA methylation signatures characteristic of their somatic tissue of origin, which favors 
their differentiation along lineages related to the donor cell, while restricting alternative cell fates. 
Such an “epigenetic memory” of the donor tissue could be reset by differentiation and serial 
reprogramming, or by treatment of iPSC with chromatin-modifying drugs. In contrast, the 
differentiation and methylation of nuclear transfer-derived pluripotent stem cells were more 
similar to classical embryonic stem cells than were iPSC, consistent with more effective 
reprogramming. Our data demonstrate that factor-based reprogramming can leave an epigenetic 
memory of the tissue of origin that may influence efforts at directed differentiation for 
applications in disease modeling or treatment.
Introduction
Direct reprogramming of somatic cells with the transcription factors Oct4, Sox2, Klf4, and 
c-Myc1 yields induced pluripotent stem cells (iPSC) with striking similarity to embryonic 
stem cells from fertilized embryos (fESC). Like fESC, iPSC form teratomas, differentiated 
tumors with tissues from all three embryonic germ layers, and when injected into murine 
blastocysts contribute to all tissues, including the germ line. iPSC from mouse embryo 
fibroblasts generate “all-iPSC mice” following injection into tetraploid blastocysts2, thereby 
satisfying the most stringent criterion of pluripotency3. Embryonic tissues are the most 
efficiently reprogrammed, producing iPSC that are nearly identical to fESC. In contrast, 
reprogramming from accessible adult tissues, most applicable for modeling diseases and 
generating therapeutic cells, is inefficient and limited by barriers related to the 
differentiation state and age of the donor’s cells456. Aged cells have higher levels of Ink4/
Arf, which limits the efficiency and fidelity of reprogramming5. Moreover, terminally 
differentiated blood cells reprogram less efficiently than blood progenitors6. As with cloning 
by nuclear transfer in frogs and mice, the efficiency and yield of reprogrammed genomes 
declines with increasing age and differentiation status of the donor cell7, and varies with the 
methylation state of the donor nucleus8.
Different tissues show variable susceptibility to reprogramming. Keratinocytes reprogram 
more readily than fibroblasts9, and iPSC from stomach or liver cells harbor fewer integrated 
proviruses than fibroblasts, suggesting they require lower levels of the reprogramming 
factors to achieve pluripotency10. When differentiated into neurospheres, iPSC from adult 
tail-tip fibroblasts retain more teratoma-forming cells than iPSC from embryonic fibroblasts, 
again indicating heterogeneity based on the tissue of origin11. Moreover, cells can exist in 
intermediate states of reprogramming that interconvert with continuous passage or treatment 
with chromatin-modifying agents1213. Although generic iPSC are highly similar to fESC, in 
practice iPSC generated from various tissues may harbor significant differences, both 
functional and molecular.
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Transcription factor reprogramming differs markedly from nuclear transfer, particularly with 
regard to DNA demethylation, which commences immediately upon transfer of a somatic 
nucleus into ooplasm14, but occurs over days to weeks during the derivation of iPSC13. 
Because demethylation is a slow and inefficient process in factor-based reprogramming, we 
postulated that residual methylation might leave iPSC with an “epigenetic memory,” and 
that methylation might be more effectively erased by nuclear transfer. Here we compare the 
differentiation potential and genomic methylation of pluripotent stem cells (iPSC, ntESC, 
and fESC), and find evidence that iPSC indeed retain a methylation signature of their tissue 
of origin.
Results
Initially we sought to compare the in vivo engraftment potential of hematopoietic stem cells 
derived from fESC, ntESC, and iPSC in a mouse model of thalassemia. However, even in 
vitro we observed strikingly different blood-forming potential; thus, we focused here instead 
on understanding this phenomenon. Our initial set of pluripotent stem cells were derived 
from the hybrid C57BL/6 x CBA (B6/CBAF1) strain carrying a deletion in the beta-globin 
locus15, which is otherwise irrelevant to this study (Fig. 1a). We isolated fESC cells from 
naturally fertilized embryos and derived ntESC cells from nuclei of dermal fibroblasts8. We 
infected early bone marrow cells (Kit+, Lin−, CD45+) or dermal fibroblasts from aged mice 
with retroviral vectors carrying Oct4, Sox2, Klf4, and Myc, and selected blood-derived and 
fibroblast-derived iPSC colonies (B-iPSC, F-iPSC). Hematopoietic progenitors and 
fibroblasts yielded a comparable frequency of reprogrammed colonies (0.02%), which 
consistent with prior reports5, was lower than the yield from fibroblasts of a juvenile mouse 
(0.1%). We characterized the fESC, ntESC, and iPSC lines for expression of Oct4 and 
Nanog by immunohistochemistry, and demonstrated multi-lineage differentiation potential 
in teratomas (Fig. 1b, c; Supplementary Fig. 1). By criteria typically applied to human 
samples and appropriate for a therapeutic model3, all stem cell lines manifest pluripotency.
Differentiation of pluripotent stem cells
To test blood potential, we differentiated multiple pluripotent stem cell clones into embryoid 
bodies (EBs), dissociated cells, and assayed for hematopoietic colony forming cells16. All 
pluripotent cells generated comparable EBs but markedly different numbers of 
hematopoietic colonies. Consistently, blood-derived B-iPSC yielded more hematopoietic 
colonies than F-iPSC (Fig. 2a). Hematopoietic colony formation from ntESC and fESC were 
higher than the iPSC lines.
We then tested differentiation into osteoblasts, a mesenchymal lineage that can be derived 
from fibroblasts1718. By alizarin red staining, a marker of osteogenic cells19, F-iPSC 
produced more sharply defined osteogenic colonies (Fig. 2b), deposited more elemental 
calcium (Fig. 2c), and showed higher expression of three osteoblast-associated genes (Fig. 
2d) than B-iPSC. By these criteria, F-iPSC show enhanced osteogenic potential, reflecting a 
propensity to differentiate towards a mesenchymal lineage. In contrast, ntESC cells behaved 
comparably to fESC in hematopoietic and osteogenic assays.
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DNA methylation of pluripotent stem cells
We hypothesized that the different pluripotent cells might harbor different patterns of 
genomic DNA methylation; thus, we performed Comprehensive High-throughput Array-
based Relative Methylation (CHARM) analysis, which interrogates ~4.6 million CpG sites, 
including almost all CpG islands and nearby sequences termed shores2021, but does not 
assess non-CpG methylation. We determined the number of differentially methylated 
regions (DMRs) between pair-wise comparisons, using a threshold area cutoff of 2, 
corresponding to a 5% false discovery rate (FDR22; Supplementary Table 1a). By this 
analysis, ntESC were most similar to fESC (only 229 DMRs), whereas F-iPSC differed most 
extensively (5304 DMRs). Relative to fESC, hypermethylated DMRs predominated for F-
iPSC (3349=63%) and B-iPSC (516=74%). Highlighting their functional differences, 5202 
DMRs were identified between B-iPSC and F-iPSC. We confirmed the results of CHARM 
analysis by bisulfite pyrosequencing of multiple loci (Supplementary Fig. 2).
Unsupervised hierarchical clustering of DMRs between B-iPSC and F-iPSC easily 
distinguished iPSC from ntESC and fESC, which cluster together (Fig. 3a). B-iPSC cluster 
nearer to ntESC and fESC than do F-iPSC, which represent a strikingly separate cluster. 
These data indicate that the methylation patterns of ntESC are more like fESC than are 
either iPSC.
Several lines of evidence support a mechanistic link between differential methylation and 
hematopoietic propensity of iPSC lines. First, literature survey of genes for the top 24 
DMRs that distinguish B-iPSC and F-iPSC links 11 to hematopoiesis and 3 to osteogenesis 
(Supplementary Table 2). Of the 11 hematopoietic loci, 10 are hypermethylated in F-iPSC 
relative to B-iPSC. Second, of 74 hematopoietic transcription factors23, 20 are in or near 
DMRs that are hypermethylated in F-iPSC versus B-iPSC, twice that predicted by chance 
(p=0.0034; Fig. 3b left panel, Supplementary Fig. 3a, and Supplementary Table 3). 
Similarly, of 764 fibroblast-specific genes, 115 are hypermethylated in B-iPSC, twice that 
predicted by chance (p=10−5; Fig 3b right panel). Given the correlation between methylation 
and transcriptional silencing24, our data suggest that iPSC harbor epigenetic marks 
antagonistic to cell lineages distinct from the donor cell type.
We asked whether DMRs that distinguish B-iPSC from fESC might allow us to identify 
their hematopoietic lineage of origin. In a separate CHARM experiment 25, we examined 
genome-wide methylation in highly purified multipotent and lineage-specific hematopoietic 
progenitors. Comparing DMRs in B-iPSC to those that define hematopoietic progenitors, we 
observed that B-iPSC cluster alongside Common Myeloid Progenitors (CMP) and distant 
from Common Lymphoid Progenitors (CLP; Supplementary Fig. 4a and Supplementary 
Table 4), which is notable given that B-iPSC were derived from Kit+, lineage-negative 
myeloid marrow precursors. Next, we asked whether the tissue of origin (bone marrow vs 
fibroblast) could be identified by the methylation state of tissue specific DMRs in F-iPSC, 
B-iPSC, and Bl-iPSC (a B lymphocyte-derived iPSC line described below). Using DMRs 
that distinguish fibroblast and bone marrow, and examining methylation in iPSCs and 
somatic cells from two different genetic backgrounds (B6CBA and B6129), we found that 
F-iPSC cluster alongside fibroblasts, and distant from bone marrow (Supplementary Fig. 
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4b). Similarly, the hematopoietic-derived B-iPSC and Bl-iPSC grouped with somatic cells 
from bone marrow. Thus, residual methylation indicates the tissue of origin of iPSC, and for 
blood-derivatives even their precise lineage, further supporting the phenomenon of 
epigenetic memory in iPSC.
Reprogrammed state of iPSC and ntESC
We postulated that the differing methylation signatures of B-iPSC, F-iPSC, and ntESC 
reflect disparate reprogramming, and confirmed this by two independent computational 
analyses. First, we overlapped DMRs that distinguish B-iPSC, F-iPSC, and ntESC from 
fESC with genes specifically expressed in undifferentiated murine fESC26. By this analysis, 
ntESC showed the fewest DMRs at loci corresponding to the most highly expressed fESC-
specific genes, and B-iPSC showed fewer DMRs at these loci than F-iPSC (Supplementary 
Fig. 5a). Second, we overlapped DMRs with the DNA binding locations for seven 
transcription factors that compose a core protein network of pluripotency27, and found the 
fewest DMRs at core transcription factor binding sites in ntESC, and less overlap in B-iPSC 
than in F-iPSC (Supplementary Table 5). These analyses indicate that F-iPSC harbor more 
residual methylation than B-iPSC at loci directly linked to the gene expression and 
pluripotency networks of fESC, whereas ntESC show the least differential methylation and 
appear closest to fESC at these critical loci.
Further analysis of Oct4 and Nanog indicates that although both are detected by 
immunohistochemistry in B-iPSC and F-iPSC (Fig. 1b), Oct4 mRNA is fully expressed 
from a demethylated promoter in both types of iPSC, whereas Nanog mRNA is sub-
optimally expressed from a promoter that retains considerable methylation in F-iPSC 
(Supplementary Fig. 6). When assessed by blastocyst chimerism, B-iPSC contribute to all 
tissues, including the germ line, whereas F-iPSC contribute only poorly (Supplementary Fig. 
7a), although they can be found in SSEA1+ germ cells of the gonadal ridge (Supplementary 
Fig. 7b). Thus, while both B-iPSC and F-iPSC generate robust multi-lineage teratomas, 
satisfying criteria for pluripotency typically applied to human cells3, broader functional 
assessments available in the mouse system confirm their differential degree of 
reprogramming. In this comparison of iPSC derived from accessible tissues of aged adult 
mice, bone marrow yields stem cells with superior features of pluripotency, but neither iPSC 
is equivalent to ntESC or fESC.
Stringently-defined pluripotent stem cells
To determine if blood-forming potential differs among cell lines that satisfy more stringent 
criteria for pluripotency, we analyzed lines derived from a uniform genetic background 
(B6/129F1) that all express a Nanog-eGFP reporter gene28, and for which pluripotency was 
demonstrated by blastocyst chimerism and transmission through the germ line (Fig. 4a, 
upper schema; Supplementary Table 6). These studies involve “secondary” iPSC lines 
derived from neural progenitor cells (NP-iPSC29) and B-lymphocytes (Bl-iPSC30) of mice 
chimerized with iPSC carrying proviruses that express doxycycline-inducible 
reprogramming factors from identical proviral integration sites. NP-iPSC and Bl-iPSC were 
compared to ntESC generated from neural progenitor cells (NP-ntESC8), blood progenitor 
cells (B-ntESC31), and fibroblasts (F-ntESC31, 32), as well as fESC.
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All cell lines were differentiated into embryoid bodies and assayed for hematopoietic colony 
forming activity16. Across multiple clones, we observed higher blood forming potential of 
iPSC derived from B lymphocytes (Bl-iPSC) than from neural progenitors (NP-iPSC; Fig. 
4b). In contrast, we observed that ntESC, regardless of tissue origin (fibroblasts, neural 
progenitors, or T-cells), and fESC displayed an equivalently robust blood forming potential 
(Fig. 4b). In this independent set of iPSC lines, qualified as pluripotent by stringent criteria, 
we again observed consistent differences in blood formation, with blood derivatives 
showing more robust hematopoiesis in vitro than neural derivatives.
Resetting differentiation propensity
Finally, we asked whether we could rescue the poor blood-forming potential of NP-iPSC by 
differentiation into hematopoietic lineages1633, followed by a tertiary round of 
reprogramming back to pluripotency by doxycycline induction of the endogenous 
reprogramming factors (Fig. 4a, lower schema). As a control, we differentiated NP-iPSCs 
into neural stem cells8, followed by tertiary reprogramming to pluripotency. Resulting iPSC 
clones were selected for expression of the Nanog-eGFP reporter and shown to express Oct4 
and Nanog by immunohistochemistry (Supplementary Fig. 8) and to chimerize murine 
blastocysts (Supplementary Fig. 9). The tertiary blood-derived B-NP-iPSC showed higher 
hematopoietic colony-forming potential than the tertiary NSC-NP-iPSC (Fig. 4b), and 
generated larger hematopoietic colonies with more cells per colony (Supplementary Fig. 
10a, b). These data indicate that the poor blood-forming potential of secondary NP-iPSC can 
be enhanced by differentiation into hematopoietic progeny, followed by tertiary 
reprogramming. In contrast, tertiary reprogramming via neural intermediates yields iPSC 
that retain poor hematopoietic potential.
The reduced blood potential of NP-iPSC might be explained by residual epigenetic marks 
that restrict blood fates or a lack of epigenetic marks that enable blood formation. We sought 
to determine whether treatment of NP-iPSC with pharmacologic modulators of gene 
expression and DNA methylation might reactivate latent hematopoietic potential. We treated 
NP-iPSC in vitro with Trichostatin A (TSA), a potent inhibitor of histone deacetylase34, and 
5-azacytidine (AZA), a methylation-resistant cytosine analogue35. After 18 days of drug 
treatment, the resulting cells displayed higher blood forming activity (NP-iPSC-TSA-AZA; 
Fig. 4b). For unclear reasons, tertiary reprogramming through blood intermediates or drug 
treatment of NP-iPSC produced altered ratios of colony sub-types, perhaps suggesting 
different efficiencies of lineage reprogramming.
Methylation in secondary and tertiary iPSC
We used CHARM to examine the methylome of the germ-line competent pluripotent stem 
cells, the tertiary reprogrammed B-NP-iPSC and NSC-NP-iPSC, and the drug-treated NP-
iPSC (Fig. 4a). In pair-wise comparisons (Supplementary Table 1b), the NP-iPSC showed 
only a small number of DMRs relative to fESC (553), fewer than the numbers of DMRs 
distinguishing ntESC from fESC (679), indicating that selection using the Nanog-GFP 
reporter and derivation from young donor tissue yields more equivalently reprogrammed 
cells. Despite equivalent Nanog-GFP expression, B lymphocyte-derived Bl-iPSC harbored 
more DMRs (1485) relative to fESC than did the NP-iPSC. Cluster dendrogram analysis, 
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employing the most variable DMRs that distinguish Bl-iPSC and NP-iPSC, showed NP-
iPSC to be more similar to fESC than are Bl-iPSC, which represent a distinct cluster (Fig. 
4c). These data suggest that neural progenitors are more completely reprogrammed to an 
ESC-like state than blood donor cells. Cluster dendrogram analysis failed to distinguish 
among NP-iPSC, ntESC, and fESC, but assessment of the overlap of DMRs with loci for 
highly expressed ESC-specific genes26 and core pluripotency transcription factor binding 
sites27 indicated differences among these three pluripotent cell types, and reveal that ntESC 
have the fewest DMRs affecting these critical loci (Supplementary Fig. 5b).
Relative to fESC, hypermethylated DMRs predominated in NP-iPSC and Bl-iPSC (417 
(75%) and 1423 (96%), respectively; Supplementary Table 1b), confirming that even when 
pluripotency is documented by stringent criteria, iPSC retain residual methylation. By 
analysis of overlapping DMRs, Bl-iPSC cluster with progenitors of the lymphoid lineage 
(CLP) rather than the myeloid lineage (Supplementary Fig. 4a; Supplementary Table 425). 
To illustrate this point, the Gcnt2 gene, which encodes the enzyme responsible for the blood 
group I antigen, and Gata2, a regulator of hematopoiesis and erythropoiesis, are both 
hypermethylated and transcriptionally silent in the lymphoid lineage25. Bl-iPSC showed 
hypermethylation at these loci relative to fESC, whereas the myeloid-derived B-iPSC did 
not (Supplementary Fig. 11). Thus, a methylation signature correctly identifies the blood 
lineage of origin of B-lymphocyte derived iPSC.
Furthermore, we found that neural-related genes tended to be differentially methylated 
between Bl-iPSC and NP-iPSC (Supplementary Fig. 3b). Treatment of NP-iPSC with TSA 
and AZA enhances blood-forming potential and increases hypomethylated DMRs (626; 
Supplementary Table 1c). We found significant overlap between these DMRs and genes 
enriched in mouse hematopoietic stem cells (MSigDG signature 
STEMCELL_HEMATOPOIETIC_UP; Supplementary Fig. 3c), suggesting that drug 
treatment erases inhibitory methylation signatures at hematopoietic loci.
We compared DMRs in iPSCs with high hematopotietic potential (B-NP-iPSC and NP-
iPSC-TSA-AZA) to those with low hematopoietic potential (NP-iPSC and NSC-NP-iPSC), 
and found that B-NP-iPSC and NP-iPSC-TSA-AZA harbored higher gene-body methylation 
of Wnt3 (Supplementary Fig. 12), a gene which along with its homologue Wnt3a plays a 
major role in blood development from fESC36. The blood-deficient NP-iPSC and NSC-NP-
iPSC lines lacked gene body methylation. While promoter methylation is repressive, gene 
body methylation is seen in active genes37. When iPSC were differentiated into embryoid 
bodies, the blood-prone NP-iPSC-TSA-AZA showed higher levels of Wnt3/3a expression 
than the blood-deficient NP-iPSC (Supplementary Fig. 13a). Interestingly, supplementation 
of the culture media with Wnt3a during embryoid body differentiation restored blood-
forming potential in the blood-deficient NP-iPSC and NSC-NP-iPSC lines, but had little 
effect on the already robust hematopoietic potential of B-NP-iPSC (Supplementary Fig. 
13b). Albeit preliminary, these data correlate differential gene body methylation and 
expression of the Wnt3 locus with enhanced blood-forming potential in iPSC lines.
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Discussion
Here we demonstrate that iPSC retain an epigenetic memory of their tissue of origin. Our 
data reveal several important principles that relate to the technical limitations inherent in the 
process of reprogramming, and which in practice influence the differentiation propensity of 
specific isolates of iPSC.
First, tissue source influences the efficiency and fidelity of reprogramming91011. From aged 
mice, blood cells were reprogrammed more closely to fESC than dermal fibroblasts, which 
yielded only incompletely reprogrammed cells. Neural progenitor-derived iPSC were most 
similar to fESC, consistent with evidence that such cells can be reprogrammed with fewer 
transcription factors38. Whereas neural progenitors are not readily accessible, iPSC can be 
generated by direct reprogramming of human blood39.
Second, analysis of DNA methylation reveals substantial differences between iPSC and 
embryo-derived ESC (ntESC and fESC). iPSC derived from non-hematopoietic cells (neural 
progenitors and fibroblasts) retain residual methylation at loci required for hematopoietic 
fate, which manifests as reduced blood-forming potential in vitro. Residual methylation 
signatures link iPSC to their tissue of origin, and even discriminate between the myeloid and 
lymphoid origins of blood-derived iPSC. Prior studies reporting residual hypermethylation 
in iPSC3722 did not establish a link between DMRs at specific loci, tissue of origin, and 
altered differentiation potential. While residual methylation is mostly repressive, we have 
shown for Wnt3 that residual gene body methylation in blood-derived iPSC is associated 
with enhanced blood potential. Interestingly, the poor blood potential of neural progenitor-
derived iPSC, which lack this epigenetic mark and express lower levels of endogenous 
Wnt3, can be enhanced by supplementing differentiating cultures with exogenous Wnt3a 
cytokine, indicating that manipulating culture conditions can overcome epigenetic barriers.
Third, the differentiation propensity and methylation profile of iPSC can be reset. When 
blood-deficient neural progenitor-derived iPSC (NP-iPSC) are differentiated into blood and 
then reprogrammed to pluripotency, their blood-forming potential is markedly increased. 
Alternatively, treatment of NP-iPSC with chromatin-modifying compounds increases blood-
forming potential and is associated with reduced methylation at hematopoietic loci. For 
some applications, epigenetic memory of the donor cell may be advantageous, as directed 
differentiation to specific tissue fates remains a challenge.
Fourth, nuclear transfer-derived ESC are more faithfully reprogrammed than most iPSC 
generated from adult somatic tissues. Like the immediate and rapid demethylation of the 
sperm pronucleus following fertilization, somatic nuclei are rapidly demethylated by nuclear 
transfer into ooplasm, prompting speculation that the egg harbors an active demethylase14. 
In contrast, demethylation is a late phenomenon in factor-based reprogramming, and likely 
occurs passively13. Studying how ooplasm erases methylation might identify biochemical 
functions that would enhance factor-based reprogramming. Failure to demethylate 
pluripotency genes is associated with intermediate or partial states of reprogramming122940, 
and knock-down of the maintenance methyltranferase DNMT1 or treatment with the 
demethylating agent 5-AZA can convert intermediate states to full pluripotency. 
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Demethylation appears passage dependent13, and reprogramming efficiency correlates with 
the rate of cell division and the passage number41. In our experiments, we compared 
pluripotent stem cells of comparable low passage number (Supplemental Table 5), but 
continued serial passage may homogenize the differentiation potential of pluripotent cell 
types.
The mRNA expression program of iPSC and fESC are strikingly similar42. Minor 
differences in mRNA and microRNA expression have been reported40, but removal of 
transgenes reduces the differences43. The Dlk1-Dio3 locus, whose expression correlates 
with capacity to generate “all-iPSC” mice44, is not differentially methylated and expressed 
in at least some iPSC lines that manifest epigenetic memory (our unpublished observations). 
Thus even the most stringently-defined iPSC might retain epigenetic memory. Importantly, 
differences between iPSC and fESC may not manifest until differentiation, when the specific 
loci that retain residual epigenetic marks are expressed, influencing cell fates. Methylation is 
but one molecular feature of “epigenetic memory” in iPSC. Faulty restoration of bivalent 
domains, which mark developmental loci with both active and repressive histone 
modifications 45, and loss of pioneer factors, which in fESC and iPSC occupy enhancers of 
genes expressed only in differentiated cells46, represent two other potential mechanisms.
Although ideal, generic iPSC may be functionally and molecularly indistinguishable from 
fESC, we have shown in practice that even rigorously selected iPSC can retain epigenetic 
marks characteristic of the donor cell that influence differentiation propensity. Epigenetic 
differences are unlikely to be essential features of iPSC, but rather reflect stochastic 
variations associated with the technical challenges of achieving complete reprogramming. 
Given that we lack reporter genes for selecting human iPSC, and cannot qualify their 
pluripotency by assaying embryo chimerism, the behavior of human cells will likely be 
influenced by epigenetic memory. Human ESC can also manifest variable differentiation 
potential47. These data highlight our limited understanding of the epigenetic heterogeneity 
of pluripotent stem cells, and the need for improved methods to ensure reprogramming of 
somatic cells to a fully naïve, “ground state” of pluripotency48.
METHODS SUMMARY
ES cells and iPSCs were cultured in ESC media containing 15% FBS, and 1,000 U/ml of 
LIF. For the reprogramming of somatic cells, retrovirus expressing Oct4, Sox2, Klf4, and 
Myc were introduced. For the somatic cells containing inducible reprogramming factors, the 
media was supplemented with 2 ng/ml of doxycycline. For DNA and RNA isolation, fESC 
or iPSCs were trypsinized and re-plated onto new tissue culture dishes for 45 minutes to 
remove feeder cells, and nucleic acids were extracted from the non-adherent cell suspension. 
Genomic DNA methylation analysis and pyrosequencing were performed by previously 
published methods2021.
Full Methods and any associated references are available in the online version of the paper 
at www.nature.com/nature.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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APPENDIX
METHODS
Tissue culture
Bl-iPSC and NP-iPSC have been described305051. The cells were cultured in standard ES 
maintenance media.
Generation of B-iPSC and F-iPSC
B-iPSC were generated from bone marrow cells collected from one-year-old B6CBAF1 
mice. Early progenitor cells (lin−, CD45+, and cKit+) were sorted by FACS (HemNeoFlow 
Facility at the Dana Farber Cancer Institute) and stained with lineage-specific antibodies 
(B220;RA3-6B2, CD19;1D3, CD3;145-2c11, CD4;GK1.5, CD8;536.7, Ter119;ter119, 
Gr-1;RB6-8C5), CD45 specific antibody (30-F11), and cKit antibody (2B8). 105 sorted cells 
were infected with retrovirus generated from pMXOct4, pMXSox2, pMXKlf41, and 
pEYK3.1cMyc52 in 6 well dishes with 0.5 ml of each viral supernatant (total 2 ml per well), 
and spun at 2500 rpm at 20C for 90 minutes (BenchTop Centrifuge, BeckmanCoulter, 
Allegra-6R). cMyc was cloned into pEYK3.1 containing two loxp sites to enable removal of 
the cMyc by Cre treatment. The reprogramming factor-infected cells were plated on to 
irradiated OP9 feeder cells in 10 cm tissue culture dish in IMDM media (Invitrogen) 
supplemented with 10% FBS, 1x penicillin/streptomycin/glutamine (Invitrogen), VEGF 
(R&D Systems, 40ng/ml), Flt (R&D Systems, 100 ng/ml), TPO (R&D Systems, 100ng/ml), 
and SCF (R&D Systems, 40ng/ml) on day 0. The media were changed on day 2. Cells were 
collected by media centrifugation and returned to culture during media changes. On day 5, 
cultured cells were trypsinized and replated on to four 10 cm dishes pre-coated with 
irradiated mouse embryonic fibroblast in ES maintenance media. Media were changed daily 
until ES-like colonies were observed. F-iPSC were generated from tail tip fibroblasts of one-
year-old B6CBAF1 mice. 106 fibroblast cells were plated onto all wells of a 6 well plate and 
spin-infected with the four viral supernatants, as for the generation of B-iPSC. Cells were 
cultured further in DMEM media (Invitrogen) supplemented with 15% FBS, 1x penicillin/
streptomycin/glutamine (Invitrogen). On day 5, the cultured cells were trypsinized, and 
replated in four 10 cm dishes on irradiated mouse embryonic fibroblast with ES maintenance 
media. Media was changed every day until ES-like colonies were observed.
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Differentiation of iPSC to hematopoietic and osteogenic lineages
Hematopoietic colony forming activity of d6 EBs differentiated from pluripotent stem cells 
was measured in methylcellulose medium with IL3, IL6, Epo, and SCF (M3434, StemCell 
Tech.) as described16. Hematopoietic colony type was determined on day 10. Colony 
identity was confirmed by leukostain analysis of cytospin preparation of the methylcellulose 
colonies. Osteogenic differentiation was performed by culturing pluripotent stem cells in 15 
μl hanging drops (800 cells/drop) in ES differentiation media16. Embryoid bodies (EB) from 
hanging drops were collected at 2 days, transferred to a 10 cm dish of non-tissue culture 
grade plastic with 10−6 M of retinoic acid, and cultured for 3 days on the shaker (50 rpm) in 
an incubator. EBs were equally distributed among 3 wells of a 6-well tissue culture dish, and 
cultured in αMEM media supplemented with 10 % FBS, 1x penicillin/streptomycin/
glutamine (Invitrogen), 2 nM triiodothyronine, 1x insulin/transferrin/triacostatin A (Gibco, 
#51300-044). The media were changed every other day. On day 11, one well of each sample 
was used to measure calcium concentration, osteogenic gene expression (RNA isolation), 
and for Alizarin Red staining. For Alizarin Red staining, cells were washed with PBS and 
fixed with 4% paraformaldehyde for 5 minutes at 20C. Fixed cells were incubated for 15 
minutes in Alizarin Red staining solution (Alizarin Red (Sigma, A5533) 2% in H2O, pH 
4-4.3 adjusted with NH4OH, filtered with 0.45uM membrane), and washed with Tris-HCl, 
pH4.0. Elemental calcium concentrations were measured by inductively coupled plasma – 
atomic emission spectroscopy (ICP-AES, HORIBA Jobin Yvon Activa-M)49 at the Center 
for Materials Science and Engineering at MIT, and three measurements were conducted to 
obtain mean and standard deviation values. To measure ionized calcium, cells were treated 
with 5% HNO3 (for dissolution of calcium molecules) and 10% HClO4 acid solutions (to 
remove organic compounds) in a cell culture flask and then briefly sonicated for 10 min. 
The solution was incubated for > 3 hrs on the titer plate shaker. The obtained values were 
converted to calcium concentration using a reference solution made by Fluka (Calcium 
Standard for AAS, TraceCERT®), and normalized by 5 × 105 initiated cells.
Quantitative RT-PCR Analysis
The expression levels of osteogenic genes (Runx2, Sp7, and Bglap) were quantified by real-
time RT-PCR with Quantifast SYBR Green RT-PCR kit (Qiagen, Hilden, Germany). Total 
RNAs (2 ug) were reverse-transcribed in a volume of 20 ul by using the SuperScript III 
First-Strand Synthesis System (Invitrogen, Carlsbad, California, USA), and the resulting 
cDNA was diluted into a total volume of 500 ul. 5 ul of this synthesized cDNA solution was 
used for analysis. For osteogenic genes, each reaction was performed in a 25 ul volume 
using the Quantifast SYBR Green RT-PCR kit (Qiagen, Hilden, Germany). The conditions 
were programmed as follows: initial denaturation at 95C for 5 min followed by 40 cycles of 
10 s at 95C and 30 s at 60C, then 1 min at 95C, 30 s at 55C, and 30 sec at 95C. For 
pluripotent genes, each reaction was performed in a 25 ul volume using using the Brilliant 
SYBR Green QPCR master mix kit (Stratagene, Cedar Creek, TX, USA). The conditions 
were programmed as follows: initial denaturation at 95C for 10 min followed by 40 cycles 
of 30 s at 95C, 1 min at 55C, and 1 min at 72C, then 1 min at 95C, 30 s at 55C, and 30 sec at 
95C. Primers used in the quantitative RT-PCR are listed in Supplementary Table 7. All of 
the samples were duplicated, and the PCR reaction was performed using an Mx3005P 
(Stratagene, Cedar Creek, TX, USA), which can detect the amount of synthesized signals 
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during each PCR cycle. The relative amounts of the mRNAs were determined using the 
MxPro program (Stratagene, Cedar Creek, TX, USA). The amount of PCR product was 
normalized to a percentage of the expression level of b-Actin. The RT-PCR products of 
Oct4, Nanog, and b-Actin were also evaluated on 0.8% agarose gels after staining with 
ethidium bromide. The cycle numbers of the PCR were reduced in order to optimize the 
difference in band intensities (Oct4, Nanog, and b-Actin were 29, 33, and 28, respectively) 
(Supplementary Table 7).
DNA methylation analysis
5ug of genomic DNA from each sample was fractionated, digested with McrBC, gel 
purified, labeled and hybridized to a CHARM microarray as previously described20, 21. For 
each probe, the averaged methylation values across the same cell type were computed and 
converted to percent methylation (p). p was used to find regions of differential methylation 
(Δp) for each pairwise cell type comparison and the absolute area of each region was 
calculated by multiplying the number of probes by Δp. For data analysis, we used area value 
2 as the cutoff to define differentially methylated regions (DMRs). Our previous study 
indicated that this cutoff corresponds to 5% false discovery rate (Doi et al. unpublished 
data). Bisulfite pyrosequencing analysis of individual regions was performed as previously 
described21. Primer sequences are provided in Supplementary Table 7.
Teratoma and chimera analysis
Teratomas were assessed by injecting 106 undifferentiated cells into the subcutaneous tissue 
above the rear haunch of Rag2/γC immunodeficient mice (Taconic), and teratoma formation 
was monitored for 3 months post injection. Collected tumors were processed by the 
Pathology Core of the Dana-Farber/Harvard Cancer Center. Chimera analysis of pluripotent 
cells was conducted by injecting GFP+ or GFP− cells into blastocysts isolated from 
C57BL/6 (GFP− or GFP+) embryos, which were collected at the two-cell stage. The 
fertilized embryo was collected from the oviduct and cultured in KSOM media (Specialty 
Media). A mouse strain expressing GFP from the human ubiquitin promoter (Jackson 
Laboratory) was used to ensure maximum expression in various tissues, and enabled 
injected cells to be distinguished from host cells. The reconstituted blastocysts were 
implanted into 2.5 day pseudopregnant CD1 females. Chimeras were allowed to develop to 
adulthood to gauge skin chimerism and germ cell transmission, or were dissected at 
embryonic day 12.5 to isolate gonad, liver, heart, and MEF for flow analysis. Gonads were 
stained with SSEA1 antibody (Hybridoma Bank) for 1 hour, and treated with APC-
conjugated mouse IgM antibody (BD Pharmingen, #550676) to detect SSEA1 positive germ 
cells by flow cytometry (LSRII, BD Biosciences, Hematology/Oncology Flow Cytometry 
Core Facility of Children’s Hospital Boston).
Generation of NSC-NP-iPSC, B-NP-iPSC, and NP-iPSC-TSA-AZA
Neural Progenitor (NP) iPSC harboring integrated proviruses carrying the four 
reprogramming factrors29 were differentiated to neural stem cells (NSC) as described53. 
Reprogramming factors in cultured NSC were induced by doxycycline, and colonies 
expressing GFP from the nanog-reporter were selected to yield NSC-NP-iPSC. NP-iPSC 
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from blood lineages (B-NP-iPSC) were obtained by differentiating the NP-iPSC via EB for 
6 days, infecting with HoxB4ERT retrovirus54, and co-culturing on OP9 in the presence of 
4-hydroxytamoxifen (4-HT) to enable isolation of hematopoietic cells16. Day 15 
hematopoietic cells were harvested, stained with CD45+ (BD Pharmingen, #557659), and 
sorted for hematopoietic cells. Only minimal hematopoietic colonies were observed on OP9 
culture in the absence of 4-HT. Harvested CD45+ hematopoietic cells were induced by 
doxycycline and colonies expressing GFP from the nanog-reporter were selected to yield B-
NP-iPSC. Methylcellulose hematopoietic colony analysis was conducted in the absence of 
4-HT as a negative control. The dissociated EBs (2×105 cells) from NP-iPSC were infected 
with HoxB4-ERT virus and then plated on methylcellulose media. Only 1.7 +/− 1.2 colonies 
(n=3) were formed in the absence of hydroxytamoxifen, which indicates the limited 
functional HoxB4 expression in the absence of 4-HT. NP-iPSC-TSA-AZA cells were 
isolated by treating cells for 9 days with Trichostatin A (TSA, 100nM) and 5-azacytidine 
(AZA, 1mM), in 3-day cycles: drug treatment occurred on two consecutive days, followed 
by one day of non-treatment. Undifferentiated colonies were recovered to conduct 
methylcellulose analysis. Wnt3a (R&D System, 1324-WN-002/CF, 40ng/ml) was added to 
EB culture media between day 2 and 4, and hematopoietic potential was tested by plating on 
methylcellulose media as described above.
Gene Enrichment analysis
We took a permutation approach to assess the enrichment of hematopoiesis and fibroblast 
related genes in DMRs. Gene lists were derived from MSigDB (http://
www.broadinstitute.org/gsea/msigdb/index.jsp) for Supplementary Figure 3c, and cell-type 
signatures are described in Cahan et al.23 for all other enrichment analyses. To identify cell-
type signatures, gene expression profiles of more than 80 distinct cell types were 
downloaded from Gene Expression Omnibus, normalized, and searched for sets of genes 
that exhibit cell type-specific expression patterns, using the template matching method 
described in Pavlidis et al.55. Enrichment P-values were calculated as the number of times 
that a random selection of genes from the 13,931 profiled met or exceeded the observed 
overlap based on 100,000 random selections. The number of randomly selected genes was 
the same as the number of genes in the DMR list. Fig. 3b (left panel): 20/74 hematopoiesis-
related transcription factors are among the 1,997 genes hypermethylated in F-iPSC vs B-
iPSC (P-value=0.00337). Fig. 3b (right panel): 115/562 fibroblast-specific genes are among 
the 1,589 genes hypermethylated in B-iPSC vs F-iPSC (P-value=0.00001). Supplementary 
Figure 3A: 12/130 liver-specific genes are among the 1,321 differentially methylated in F-
iPSC vs B-iPSC (P-value=0.58178). Supplementary Figure 3B: 250/1764 neural-specific 
genes are among the 1,805 differentially methylated in Bl-iPSC vs. NP-iPSC (P-
value=0.05813). Supplementary Figure 3C: 63/526 genes up-regulated in hematopoietic 
stem cells are among the 1,133 genes hypomethylated in NP-iPSC-TSA-AZA vs NP-iPSC 
(P-value=0.00116).
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Figure 1. Pluripotent stem cells and their characterization
a, Experimental schema. fESC, ntESC, F-iPSC, and B-iPSC were derived from B6/CBA F1 
mice by reprogramming and/or cell culture, characterized for pluripotency by criteria 
applied to human cells, followed by differentiation analysis for osteogenic or hematopoietic 
lineages. b, Expression of pluripotency markers NANOG and OCT4 by 
immunohistochemistry. 4,6-Diamidino-2-phenylindole (DAPI) staining for total cell 
content. Feeder fibroblasts serve as internal negative controls. c, Teratoma analysis: tumor 
histology from indicated cell lines shows highly cystic structures consisting of differentiated 
elements of all three embryonic germ layers. Scale bar, 200μm.
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Figure 2. Differentiation of cell lines
a, Hematopoietic colony number per 100,000 EB cells differentiated from indicated cell 
lines. b, Alizarin Red staining of osteogenic cultures of B-iPSC (left) and F-iPSC (right). 
Top: 3 cm culture dish; Bottom: stained colonies; scale bar, 500 μm. c, Quantification of 
elemental calcium by inductively coupled plasma – atomic emission spectroscopy49 in 
5×105 cells after osteogenic differentiation of indicated cell lines. d, Q-PCR of osteogenic 
genes, Bglap, Sp7, and Runx2 in indicated cell lines after osteogenic differentiation. Gene 
expression was normalized to Actin. n=number of independent clones tested. Error bars=s.d.
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Figure 3. Analysis of methylation in stem cell lines
a, Cluster dendrogram using probes from DMRs that distinguish B-iPSC and F-iPSC. Cell 
clones are described in Supplemental Table 5. b, Enrichment of DMRs for hematopoiesis 
and fibroblast-related transcription factors in B-iPSC and F-iPSC, relative to chance (blue 
histogram; 100,000 random permutations). Left panel: 20 of 74 hematopoiesis-related 
transcription factors overlap DMRs hypermethylated in F-IPSC (p=0.0034); Right panel: 
115 of 764 fibroblast-specific genes overlap DMRs hypermethylated in B-iPSC (p=10−5).
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Figure 4. Stringently-defined pluripotent stem cells and their characterization
a, Experimental schema. Four horizontal lines indicate integrated proviruses carrying dox-
inducible reprogramming factors in some experiments. Characteristics of individual clones 
in all subsequent panels can be found in Supplemental Table 5. b, Hematopoietic colony 
number per 100,000 EB cells differentiated from indicated cell lines. n=number of 
independent clones tested. Error bars=s.d., added for clones repeated three or more times. c, 
Cluster dendrogram using probes from DMRs that distinguish Bl-iPSC and NP-iPSC.
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